Table 1.
Demographic and clinical data
| Variable | Total population (n = 136) | P value with combined frailty & T score |
|---|---|---|
| Age at time of surgery, median (IQR) | 63 (54–70) | .009 |
| Race, n (%) | .892 | |
| White | 90 (66.2) | |
| Nonwhite | 46 (33.8) | |
| BMI (kg/m2), median (IQR) | 28.8 (26.4–32.8) | .077 |
| Date of surgery, n (%) | .282 | |
| 2014–2016 | 37 (27.2) | |
| 2017–2019 | 99 (72.8) | |
| Surgery technique, n (%) | .329 | |
| Open | 54 (39.7) | |
| Robotic | 43 (31.6) | |
| Laparoscopic | 28 (20.6) | |
| Other | 11 (8.09) | |
| Primary surgeon division, n (%) | .819 | |
| Urology | 119 (87.5) | |
| Other | 17 (12.5) | |
| Surgery types, n (%) | ||
| Oncology | 118 (86.6) | .510 |
| Non-oncology | 18 (13.4) | |
| ASA, n (%) | .116 | |
| 1–2 | 35 (25.7) | |
| 3–4 | 101 (74.3) | |
| CCI, n (%) | .070 | |
| 0 | 61 (44.9) | |
| 1–2 | 14 (10.3) | |
| ≥ 3 | 61 (44.9) | |
| ECOG, n (%) | .174 | |
| 0 | 96 (70.6) | |
| 1–2 | 40 (29.4) | |
| Hemoglobin (g/dL) | ||
| Patients with abnormal levels, n (%) | 55 (40.4) | .022 |
| Creatinine (mg/dL) | ||
| Patients with abnormal levels, n (%) | 35 (25.7) | .430 |
| GFR (mL/min/1.73 m2) | ||
| Patients with abnormal levels, n (%) | 38 (27.9) | .661 |
| Platelets (10E3/μL) | ||
| Patients with abnormal levels, n (%) | 21 (15.4) | .065 |
| Free testosterone (pg/mL), median (IQR) | 43.1 (32.5–55.3) | – |
| Normal free T, n (%) | 100 (73.5) | |
| Low free T, n (%) | 36 (26.5) | |
| Total testosterone (ng/dL), median (IQR) | 261 (207–346) | – |
| Normal total T, n (%) | 54 (39.7) | |
| Low total T, n (%) | 82 (60.3) | |
| Low free T and low total T, n (%) | 31 (22.8) | |
| Frailty score, n (%) | – | |
| 0 | 70 (51.5) | |
| 1 | 35 (25.7) | |
| 2 | 22 (16.2) | |
| 3 | 7 (5.2) | |
| 4 | 1 (0.7) | |
| 5 | 1 (0.7) | |
| Frailty, n (%) | – | |
| Nonfrail (score 0–1) | 105 (77.2) | |
| Frail (score 2–5) | 31 (22.8) |